Tscan therapeutics to host virtual kol event to discuss updated results from phase 1 heme malignancies study presented at the 2024 tandem meetings of astct and cibmtr

Tscan's abstract selected by the tandem meetings to receive a best abstracts award company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse waltham, mass., feb. 14, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the company will host a virtual key opinion leader (kol) event to discuss updated results from its phase 1 heme malignancies study and highlights from its oral presentation at the 2024 tandem meetings: transplantation & cellular therapy meetings of the american society for transplantation and cellular therapy (astct®) and the center for international blood and marrow transplant research (cibmtr®) on monday, february 26, 2024, at 8:00 a.m.
TCRX Ratings Summary
TCRX Quant Ranking